|
HY-100195-25mg
|
MedChemexpress LLC
|
SAR-020106 [CAS 1184843-57-9]
|
|
Cancer-Kinase/protease
|
|
|
HY-100195-5mg
|
MedChemexpress LLC
|
SAR-020106 [CAS 1184843-57-9]
|
|
Cancer-Kinase/protease
|
|
|
HY-100195-50mg
|
MedChemexpress LLC
|
SAR-020106 [CAS 1184843-57-9]
|
|
Cancer-Kinase/protease
|
|
|
HY-100208-10mg
|
MedChemexpress LLC
|
HC-067047 [CAS 883031-03-6]
|
|
Cancer-programmed cell death
|
|
|
HY-100208-100mg
|
MedChemexpress LLC
|
HC-067047 [CAS 883031-03-6]
|
|
Cancer-programmed cell death
|
|
|
HY-100208-25mg
|
MedChemexpress LLC
|
HC-067047 [CAS 883031-03-6]
|
|
Cancer-programmed cell death
|
|
|
HY-100208-5mg
|
MedChemexpress LLC
|
HC-067047 [CAS 883031-03-6]
|
|
Cancer-programmed cell death
|
|
|
HY-100208-50mg
|
MedChemexpress LLC
|
HC-067047 [CAS 883031-03-6]
|
|
Cancer-programmed cell death
|
|
|
HY-100223-10mg
|
MedChemexpress LLC
|
Calpeptin [CAS 117591-20-5]
|
|
COVID-19-immunoregulation
|
|
|
HY-100223-100mg
|
MedChemexpress LLC
|
Calpeptin [CAS 117591-20-5]
|
|
COVID-19-immunoregulation
|
|
|
HY-100223-25mg
|
MedChemexpress LLC
|
Calpeptin [CAS 117591-20-5]
|
|
COVID-19-immunoregulation
|
|
|
HY-100223-5mg
|
MedChemexpress LLC
|
Calpeptin [CAS 117591-20-5]
|
|
COVID-19-immunoregulation
|
|
|
HY-100223-50mg
|
MedChemexpress LLC
|
Calpeptin [CAS 117591-20-5]
|
|
COVID-19-immunoregulation
|
|
|
HY-100234-10mg
|
MedChemexpress LLC
|
DREADD agonist 21 [CAS 56296-18-5]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-100234-100mg
|
MedChemexpress LLC
|
DREADD agonist 21 [CAS 56296-18-5]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-100234-2mg
|
MedChemexpress LLC
|
DREADD agonist 21 [CAS 56296-18-5]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-100234-25mg
|
MedChemexpress LLC
|
DREADD agonist 21 [CAS 56296-18-5]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-100234-5mg
|
MedChemexpress LLC
|
DREADD agonist 21 [CAS 56296-18-5]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-100234-50mg
|
MedChemexpress LLC
|
DREADD agonist 21 [CAS 56296-18-5]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-100234A-10mg
|
MedChemexpress LLC
|
DREADD agonist 21 (dihydrochloride) [CAS 2250025-92-2]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-100234A-100mg
|
MedChemexpress LLC
|
DREADD agonist 21 (dihydrochloride) [CAS 2250025-92-2]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-100234A-25mg
|
MedChemexpress LLC
|
DREADD agonist 21 (dihydrochloride) [CAS 2250025-92-2]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-100234A-5mg
|
MedChemexpress LLC
|
DREADD agonist 21 (dihydrochloride) [CAS 2250025-92-2]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-100234A-50mg
|
MedChemexpress LLC
|
DREADD agonist 21 (dihydrochloride) [CAS 2250025-92-2]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-100240-1mg
|
MedChemexpress LLC
|
Lodelaben [CAS 111149-90-7]
|
|
Metabolism-protein/nucleotide metabolism
|
|
